

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number  
**WO 03/020702 A2**

(51) International Patent Classification<sup>7</sup>:

C07D

(21) International Application Number: PCT/US02/27803

(22) International Filing Date:

3 September 2002 (03.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/316,320 31 August 2001 (31.08.2001) US

(71) Applicants: THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, Office of Technology Transfer, New York, NY 10021-6399 (US). CHILDREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnet Avenue, Cincinnati, OH 45229-3039 (US).


(72) Inventors: GREENGARD, Paul; 362 East 69th Street, New York, NY 10021 (US). REPASKE, David; 148 Brushwood Drive, Loveland, OH 45140 (US). SNYDER, Gretchen; 317 North Broad Street, Apartment 802, Philadelphia, PA 19107 (US).

(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: PHOSPHODIESTERASE ACTIVITY AND REGULATION OF PHOSPHODIESTERASE 1-B-MEDIATED SIGNALING IN BRAIN



WO 03/020702 A2

(57) Abstract: The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1 B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.